Gyre Therapeutics (GYRE) Asset Utilization Ratio (2011 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Asset Utilization Ratio of 0.71 for Q1 2026, down 9.55% year-over-year from 0.79 in Q1 2025, and little changed quarter-over-quarter from 0.72 in Q4 2025.
Gyre Therapeutics (GYRE) Asset Utilization Ratio (2011 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Asset Utilization Ratio for 15 consecutive years, with 0.71 the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Utilization Ratio fell 9.55% year-over-year to 0.71; the TTM figure through Mar 2026 stood at 0.71 (down 9.55% YoY), while the FY2025 annual figure was 0.8, down 8.51% from the prior year.
- Asset Utilization Ratio held at 0.71 in Q1 2026 per GYRE's latest filing, from 0.72 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 16.8 in Q3 2023 and bottomed at 0.06 in Q3 2022.
- Historically, Asset Utilization Ratio has averaged 2.37 across 5 years, with a median of 0.84 in 2024.
- Annual changes were most pronounced in 2023 — Asset Utilization Ratio soared 29964.01% — and 2024, when it plunged 94.92%.
- Gyre Therapeutics' Asset Utilization Ratio stood at 1.77 in 2022, then gained by 1.5% to 1.79 in 2023, then tumbled by 52.95% to 0.84 in 2024, then slipped by 15.11% to 0.72 in 2025, then declined by 0.41% to 0.71 in 2026.
- Business Quant data shows GYRE's Asset Utilization Ratio at 0.71 in Q1 2026, 0.72 in Q4 2025, and 0.69 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 0.66 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.66 |
| Mar 31, 2026 | 0.71 |
| Dec 31, 2025 | 0.72 |
| Sep 30, 2025 | 0.69 |
| Jun 30, 2025 | 0.72 |
| Mar 31, 2025 | 0.79 |
| Dec 31, 2024 | 0.84 |
| Sep 30, 2024 | 0.85 |
| Jun 30, 2024 | 0.92 |
| Mar 31, 2024 | 0.97 |
| Dec 31, 2023 | 1.79 |
| Sep 30, 2023 | 16.80 |
| Jun 30, 2023 | 10.00 |
| Mar 31, 2023 | 2.44 |
| Dec 31, 2022 | 1.77 |
| Sep 30, 2022 | 0.06 |
| Jun 30, 2022 | 0.09 |
| Mar 31, 2022 | 0.14 |
| Dec 31, 2021 | 0.11 |
| Sep 30, 2021 | 0.08 |